Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05085548 · ClinicalTrials.gov registry record · Phase 1
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
A Phase 1 study of Solid Tumor Malignancies and Advanced Pancreatic Cancer, sponsored by ProDa BioTech.
- Active
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT05085548 is a Phase 1 study of Solid Tumor Malignancies and Advanced Pancreatic Cancer that is active but no longer recruiting, run by ProDa BioTech. The registered enrollment target is 58 participants, below the 190-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05085548, a Phase 1 study of Solid Tumor Malignancies and Advanced Pancreatic Cancer, is active but no longer recruiting, sponsored by ProDa BioTech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is a first-in-human, Phase I study to assess the safety of ProAgio in participants with advanced solid tumor malignancies including pancreatic cancer.
Conditions Studied
Interventions
- DRUG ProAgio Dose Levels (DL) 1,2,3
- DRUG ProAgio Dose Levels (DL) 4,5,6
- DRUG ProAgio Dose Levels 4a,5a,6a
Study Locations (1)
Maryland
- National Cancer Institute - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-10-29 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05085548
The ClinicalTrials.gov registry entry for NCT05085548 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (69% lower). The listed sponsor is ProDa BioTech, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 3 interventions - of which ProAgio Dose Levels (DL) 1,2,3 is the first listed.
NCT05085548 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05085548 about?
NCT05085548 is a clinical study titled "ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies". The study is a first-in-human, Phase I study to assess the safety of ProAgio in participants with advanced solid tumor malignancies including pancreatic cancer.
What is the current status of trial NCT05085548?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2021-10-29. Estimated completion is 2026-01.
What conditions does trial NCT05085548 study?
This clinical trial studies the following conditions: Solid Tumor Malignancies, Advanced Pancreatic Cancer.
What interventions are being tested in trial NCT05085548?
The interventions under investigation include: ProAgio Dose Levels (DL) 1,2,3 (DRUG), ProAgio Dose Levels (DL) 4,5,6 (DRUG), ProAgio Dose Levels 4a,5a,6a (DRUG).
Who is sponsoring clinical trial NCT05085548?
This trial is sponsored by ProDa BioTech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05085548 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.